Additional Med-eMonitors Ordered for Stroke Prevention Health Safety-Monitoring Program
InforMedix Holdings, Inc. (OTCBB: IFMX; “InforMedix”), a leading provider of technology-based solutions focused on improving medication adherence and patients’ overall health status, announced that the Aetna Foundation, the independent charitable and philanthropic arm of Aetna, Inc. (NYSE: AET), has funded a study at the University of Pennsylvania Health System (UPHS) utilizing InforMedix’s Med-eMonitor System in patients with high risk of stroke and bleeding complications. InforMedix’s Med-eMonitor is an interactive “smart pillbox” that is intended to enable patients to manage complex medication regimens and chronic illnesses at home. This program extends a previously successful study of Med-eMonitors by UPHS.
According to Troy Brennan, M.D., Senior Vice President and Chief Medical Officer of Aetna, “The Aetna Foundation is proud to sponsor the expansion of this highly successful initial program by making it available to additional patients and for a more extended time period. We believe it is important that Aetna take the lead in supporting innovative new techniques and technologies that improve health outcomes by monitoring patients in their homes and rapidly report the results. Aetna is supportive of the approach embodied in this program at Penn, as we believe that these patients will benefit by being better able to achieve their optimal health through improved medication and care plan adherence.”
“Fortune 500 companies and other large organizations worldwide are investing heavily to bring a new generation of home health monitoring appliances into routine use in patient homes,” said Bruce A. Kehr, M.D., InforMedix’s Chairman and Chief Executive Officer. “We appreciate Aetna’s pioneering role as a leading health insurer to support Drs. Stephen Kimmel and Kevin Volpp at the University of Pennsylvania School of Medicine in providing for the expansion of their initial program’s success to include a larger population.”
According to Drs. Stephen Kimmel and Kevin Volpp, “We view this program, which can only be done with the InforMedix technology, as a potentially new type of healthcare intervention that will plausibly improve patient outcomes and lower health care costs. This approach could give patients at risk of stroke and medication-related side-effects an advantage that they could not receive through typical approaches at other anticoagulation clinics. Ultimately, if successful, this approach could be used for many different medications and medical conditions.”
Impressed by the preliminary results of the program thus far, the Aetna Foundation has committed to expand both the number of patients enrolled from twenty to one hundred and the length of the program from three months to six months.
This novel, rewards-based program uses incentives including a lottery system to reward patients who adhere properly to their medications and has already successfully enrolled and treated patients who are currently taking anticoagulant medication. This “blood thinner” medication is used to prevent blood clots from forming in the body that cause life-threatening strokes and pulmonary embolism (an often fatal blood clot in the lungs). Taking too little medication results in increased incidence of stroke and pulmonary embolism, while taking too much medication may cause life-threatening excessive bleeding.
Every forty-two seconds in the United States, someone experiences a stroke. This fact translates into approximately 760,000 new or recurrent strokes in the United States each year. It is the second leading cause of mortality in the world after cardiovascular disease, the third leading cause of death in the United States, and is the leading cause of long-term disability. The annual cost of stroke related care in the U.S. was projected to exceed $58 billion in 2006. (Medscape Neurology & Neurosurgery 3(1), 2001. Managed Healthcare Executive, April 1, 2006, and the American Stroke Association (ASA).)
The Penn researchers include: Kevin Volpp, M.D., Ph.D., Assistant Professor of Medicine and Health Care Systems, University of Pennsylvania School of Medicine and the Wharton School; and Stephen E. Kimmel, M.D., M.S.C.E., Director, Cardiovascular Epidemiology, and Associate Professor of Medicine & Epidemiology University of Pennsylvania School of Medicine.
About InforMedix
InforMedix, based in Rockville, MD, has developed the Med-eMonitor System as The Medication Adherence Solution for disease management and consumer products markets; delivering peace-of-mind to patients and their loved ones, improved independent living, and better health outcomes. InforMedix has integrated a portable patient-interactive monitoring device, hardware, software and call center monitoring to enable disease management programs, chronically ill patients and their loved ones, and medical researchers to efficiently monitor and manage patients' medication and care plan adherence, clinical response, and drug safety. To find out more about InforMedix, Inc., (OTCBB: IFMX - News), visit the Company website at www.informedix.com.
Safe Harbor Statement
This press release may contain forward looking statements that involve risks and uncertainties, including statements regarding our business strategy and development plans, plans for entering into new businesses, anticipated sources and uses of funds and other statements regarding our plans, objectives, expectations and intentions that are not historical facts. Because these forward-looking statements involve risks and uncertainties, actual results could differ materially from those discussed in this press release. These risks and uncertainties are described in greater detail in the reports that we file with the Securities and Exchange Commission. Our actual results, performance or achievements may vary materially from those expressed or implied in any forward-looking statements. All forward-looking statements reflect our beliefs and expectations as of the date of this press release and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise.
The Investor Relations Group
Mike Graff / Susan Morgenbesser, 212-825-3210
mgraff@investorrelationsgroup.com / smorgenbesser@investorrelationsgroup.com